ATE375169T1 - Modifizierte peptide enthaltende pharmazeutische präparationen - Google Patents

Modifizierte peptide enthaltende pharmazeutische präparationen

Info

Publication number
ATE375169T1
ATE375169T1 AT01945007T AT01945007T ATE375169T1 AT E375169 T1 ATE375169 T1 AT E375169T1 AT 01945007 T AT01945007 T AT 01945007T AT 01945007 T AT01945007 T AT 01945007T AT E375169 T1 ATE375169 T1 AT E375169T1
Authority
AT
Austria
Prior art keywords
peptidel
amino acid
pharmaceutical preparations
preparations containing
containing modified
Prior art date
Application number
AT01945007T
Other languages
English (en)
Inventor
Frank Mattner
Wolfgang Zauner
Walter Schmidt
Michael Buschle
Original Assignee
Intercell Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Ag filed Critical Intercell Ag
Application granted granted Critical
Publication of ATE375169T1 publication Critical patent/ATE375169T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT01945007T 2000-04-14 2001-04-17 Modifizierte peptide enthaltende pharmazeutische präparationen ATE375169T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT6572000 2000-04-14
PCT/EP2001/004313 WO2001078767A2 (en) 2000-04-14 2001-04-17 Pharmaceutical preparations comprising modified peptides

Publications (1)

Publication Number Publication Date
ATE375169T1 true ATE375169T1 (de) 2007-10-15

Family

ID=3678333

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01945007T ATE375169T1 (de) 2000-04-14 2001-04-17 Modifizierte peptide enthaltende pharmazeutische präparationen

Country Status (7)

Country Link
US (1) US20030095979A1 (de)
EP (1) EP1272215B1 (de)
JP (1) JP2003531128A (de)
AT (1) ATE375169T1 (de)
AU (1) AU2001267349A1 (de)
DE (1) DE60130877T2 (de)
WO (1) WO2001078767A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410173B (de) * 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
US20050250716A1 (en) * 2001-12-07 2005-11-10 Intercell Ag Immunostimulatory oligodeoxynucleotides
JP2005533855A (ja) 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト 病原性ウイルスからの別のリーディングフレームによりコードされる抗原
CA2484339A1 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
SI1601770T1 (sl) 2003-03-04 2010-01-29 Intercell Ag Streptococcus pyogenes antigeni
US7704514B2 (en) 2003-03-24 2010-04-27 Intercell Ag Vaccines
AU2004226262A1 (en) 2003-03-31 2004-10-14 Intercell Ag Staphylococcus epidermidis antigens
CN1774447B (zh) 2003-04-15 2011-04-06 英特塞尔股份公司 肺炎链球菌抗原
AU2004235952A1 (en) 2003-05-07 2004-11-18 Intercell Ag Streptococcus agalactiae antigens I + II
US20080175856A1 (en) 2003-05-30 2008-07-24 Intercell Ag Enterococcus Antigens
TWI358301B (en) 2003-07-11 2012-02-21 Intercell Ag Hcv vaccines
CA2583026A1 (en) * 2004-10-29 2006-05-04 Intercell Ag Hcv vaccines for chronic hcv patients
ATE494901T1 (de) * 2004-11-09 2011-01-15 Celtek Bioscience Llc Zusammensetzung und verfahren zur erhöhung der apoptose in krebszellen
EP2292645A3 (de) 2006-07-07 2011-05-25 Intercell AG Kleine Streptococcus-pyogenes-Antigene und Verwendung dafür
CN101516905A (zh) 2006-09-15 2009-08-26 英特塞尔股份公司 疏螺旋体属抗原
EP1923069A1 (de) 2006-11-20 2008-05-21 Intercell AG Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
EP2266592A3 (de) 2007-01-12 2012-08-08 Intercell AG Schützende Proteine von S. agalactiae, Kombinationen davon und Verwendungsverfahren dafür
CA2685805A1 (en) 2007-05-02 2008-11-13 Intercell Ag Klebsiella antigens
US20100203075A1 (en) 2007-06-18 2010-08-12 Intercell Ag Chlamydia antigens
CA2718473A1 (en) 2008-03-17 2009-09-24 Intercell Ag Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto
WO2010089340A2 (en) 2009-02-05 2010-08-12 Intercell Ag Peptides protective against e. faecalis, methods and uses relating thereto
WO2010092176A2 (en) 2009-02-13 2010-08-19 Intercell Ag Nontypable haemophilus influenzae antigens
WO2012139094A2 (en) 2011-04-08 2012-10-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of developing a vaccine using peptide-poly ic complexes
EP3415160B1 (de) 2014-03-04 2021-08-18 Klinikum der Universität München Aus enterococcus abgeleitete polypeptide und deren verwendung zur impfung und erstellung von therapeutischen antikörpern
EP3363459A1 (de) 2017-02-17 2018-08-22 Alexander Klimka Polypeptid-epitope von s. aureus und entsprechende monoklonale antikörper zur behandlung von infektionen und immundiagnose

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5726292A (en) * 1987-06-23 1998-03-10 Lowell; George H. Immuno-potentiating systems for preparation of immunogenic materials
US5824315A (en) * 1993-10-25 1998-10-20 Anergen, Inc. Binding affinity of antigenic peptides for MHC molecules
WO1996037107A1 (en) * 1995-05-23 1996-11-28 The Scripps Research Institute Antigen-specific activation of unprimed cd8+ t cells
AU716676B2 (en) * 1995-05-24 2000-03-02 Hawaii Biotech, Inc. Subunit vaccine against flavivirus infection
JP4163253B2 (ja) * 1995-08-18 2008-10-08 スローン−ケッタリング インスティチュート フォー キャンサー リサーチ 熱ショックタンパク質に基づくワクチンおよび免疫療法

Also Published As

Publication number Publication date
WO2001078767A3 (en) 2002-02-28
EP1272215A2 (de) 2003-01-08
WO2001078767A2 (en) 2001-10-25
JP2003531128A (ja) 2003-10-21
EP1272215B1 (de) 2007-10-10
DE60130877D1 (de) 2007-11-22
US20030095979A1 (en) 2003-05-22
AU2001267349A1 (en) 2001-10-30
DE60130877T2 (de) 2008-07-17

Similar Documents

Publication Publication Date Title
ATE375169T1 (de) Modifizierte peptide enthaltende pharmazeutische präparationen
AU764589B2 (en) Pharmaceutical compounds for the inhibition of hepatitis C virus NS3 protease
IL92853A0 (en) Human insulin analogues,their preparation and pharmaceutical compositions containing them
AU633913B2 (en) Novel tnf-inhibit proteins and their preparation
KR880009045A (ko) 혈액 응고 방지성 펩티드
BG102714A (en) Pharmaceutical composition for immunomodulation based on peptides and adjuvants
HRP980203B1 (en) Modified tnf "alpha" molecules, dna encoding such modified tnf "alpha" molecules and vaccines comprising such modified tnf "alpha" molecules and dna
EP1884247A3 (de) Gastrinzusammensetzungen und -formulierungen sowie Verfahren zu deren Herstellung und Verwendung
AU2003264514A1 (en) Wt1 substitution peptides
MY149527A (en) Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
TR199802534T2 (xx) Leptin (OB Protein) fragmanlar�
Shinkai et al. Amino acid sequence of cytochrome c 3 from Desulfovibrio vulgaris, Miyazaki
HUP0105094A2 (hu) IGF-I- és IGF-II-gátló növekedési hormont leadó hormon antagonista analógjai és alkalmazásuk
ATE392428T1 (de) Arzneimittel enthaltend analgetische peptide
KR910007960A (ko) 항응고성 펩티드
ATE42308T1 (de) Pharmakologisch aktive peptide.
NO942360L (no) Vaksine og polypeptider som er nyttige for denne
CA2423004A1 (en) Peptide inhibitors of hiv entry
Corran et al. The tryptic peptides of rabbit muscle triose phosphate isomerase
CA2164712A1 (en) Trifunctional antithrombin and antiplatelet peptides
CA2375224A1 (en) Human antithrombin variants
ATE305478T1 (de) Topoisomerase-ii inhibitoren
Vered et al. Partial amino acid sequence of porcine elastase II: active site and the activation peptide regions
Volkova et al. Synthetic fragments of the NS1 protein of the tick-borne encephalitis virus exhibiting a protective effect
RU94036770A (ru) Домен ингибитора протеазы, днк, вектор, клетка, способ получения домена, фармацевтическая композиция, применение домена

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1272215

Country of ref document: EP

REN Ceased due to non-payment of the annual fee